| Active substance | Belzutifan |
| Holder | MSD Belgium BV/SRL |
| Status | closed |
| Indication | Belzutifan (Welireg®) is indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for VHL associated, localized renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumours (pNET), and for whom localized procedures are unsuitable. |
| Public documents | Approbation |
| Last update | 31/07/2026 |